Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.12 +1.50 (+1.48%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
96 97 Next >
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly... 
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal. 
Via Investor's Business Daily
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Exploring MERCK & CO. INC.'s Technical Signals and Breakout Potential. 
Via Chartmill
Performance Comparison: Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Check Out What Whales Are Doing With MRK
Via Benzinga
Merck to Acquire EyeBio
From Merck & Co., Inc.
Via Business Wire
No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse. 
Via InvestorPlace
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence
Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing... 
Via Benzinga
Merck Announces Third-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study
Merck's KEYNOTE-522 trial shows Keytruda combined with chemotherapy significantly improves overall survival in high-risk early-stage triple-negative breast cancer patients compared to chemotherapy... 
Via Benzinga
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
For those who appreciate value investing, MERCK & CO. INC. (NYSE:MRK) is a compelling option with its solid fundamentals. 
Via Chartmill
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
Via Benzinga
S&P 500 Plays And One Dow Jones Giant Lead Five Stocks Near Buy Points
These five names are showing relative strength. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with... 
Via Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
The company passed investors' bar for success in a study of a head-and-neck cancer treatment. 
Via Investor's Business Daily
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
The billionaire hedge fund manager doesn't need dividend income. But he'll get more of it after his Q1 purchases. 
Via The Motley Fool
Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day
Summer has arrived on Wall Street! Discover three cheap stocks to buy with solid fundamentals to boost your profitability this season. 
Via InvestorPlace
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
5 Stocks Powering The Dow ETF Year To Date
While most of the stocks in the ETF portfolio have been rising this year, these five that have been leading the way higher. 
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches
With the market potentially posing some challenges, investors may find comfort in considering these safe haven stocks to buy. 
Via InvestorPlace
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
It depends on what your goals, objectives, and risk tolerances are. 
Via Talk Markets
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.